The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased Emergent Biosolutions Inc. (NYSE: EBS) securities between April 24, 2020 and April 16, 2021.
According to the Emergent Bio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Emergent’s Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent’s facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants’ public statements about Emergent’s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.
If you suffered a loss in Emergent Bio you have until June 21, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.